AASLD2012: 预测恩替卡韦单药治部分病毒学应答

StephenW

预测恩替卡韦单药治疗慢性乙型肝炎96周部分病毒学应答的风险因素
CONTROL ID: 1415171
PRESENTATION TYPE: Oral or Poster
CURRENT CATEGORY: Hepatitis B
CURRENT DESCRIPTORS: I02. Treatment and Clinical Trials
TITLE: The risk factors and predictors for partial virological response to entecavir monotherapy at week 96 in chronic hepatitis B
AUTHORS (FIRST NAME, LAST NAME): Jie Luo1, Xiangyong Li1, Yuankai Wu1, Yihua Pang1, Guoli Lin1, Xiao Zhang1, Yutian Chong1
Institutional Author(s):
INSTITUTIONS (ALL): 1. Infectious Disease, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
ABSTRACT BODY: Objective To analyze the risk factors of partial virological response(PVR) to ETV monotherapy at week 96, and to predict treatment efficacy by HBVDNA level at each time-point of follow-up.
Methods PVR to ETV monotherapy was defined as a >1 log IU/mL decline in HBVDNA from baseline but a detectable (≥100IU/mL)load at week 48 or 96. Virological response (VR) was defned as undetectable HBVDNA(<100IU/mL) at any time point during ETV therapy. A total of 175 patients who completed 2 years of ETV monotherapy were retrospecetively analyzed. The univariate and multivariate Logistic regression model were applied for high risk factors analysis. The ROC curves of the HBVDNA level or the HBV DNA reduction from baseline was used to predict VR at different time points.The area under the receiver operating characteristic curve (AUC) was used to fnd the optimal time point.
Results High baseline HBVDNA levels (OR,2.053; 95%CI,1.117-3.771; P=0.020) and virological non-response at week 24(OR,4.191; 95%CI,1.090-16.111; P=0.037) and week 48 (OR,3.826; 95%CI,0.960-15.240; P=0.057) to ETV monotherapy were the independent risk factors for a PVR at week 96. VR was achieved in 115(66.7%),147(86.0%),154(89.5%),155(90.1%),159(92.4%)patients at week 12,24,48,72 and 96,respectively. The AUC values of the HBVDNA level were consistently higher than those of HBVDNA reduction from baseline at different time points.The AUC at week 48 was better than that at week 24 and 72 for predicting VR at week 96.
Conclusion High baseline HBVDNA level, virological non-response at weeks 24 and 48 were the independent risk factors of partial viological response to ETV monotherapy at week 96. HBVDNA<100IU/ml at week 48 is a good predictor for VR at week 96 during follow-up.

StephenW

部分病毒学应答（PVR）的危险因素进行分析的目的，ETV单药治疗96周，并预测治疗疗效HBVDNA水平在各时间点的后续。
方法PVR ETV单药治疗被定义为一个> 1日志IU / mL的下降，HBVDNA基线，但在48周或96周（≥100IU/mL）可检测的负载。病毒学应答（VR）defned检测不到的HBVDNA（100IU/mL）ETV治疗期间的任何时间点。 retrospecetively分析，共有175例患者完成2年的ETV单药治疗。应用单因素和多因素Logistic回归模型的高危因素分析。 HBVDNA水平从基线降低HBV DNA的ROC曲线被用来预测VR下不同时间百分点。面积受试者工作特征曲线（AUC）被用来FND的最佳时间点。
结果基线HBVDNA水平（OR，2.053; 95％CI ,1.117-3 0.771，P = 0.020）和病毒学反应在第24周（OR，4.191; 95％CI ,1.090-16 0.111，P = 0.037）和48周的独立危险因素（OR，3.826; 95％CI ,0.960-15 .240，P = 0.057）ETV单药治疗96周的P​​VR。 115（66.7％），147（86.0％），154（89.5％），155（90.1％），159例（92.4％），在12,24,48,72和96周，分别取得了VR。 AUC值的HBVDNA水平始终高于HBVDNA从基线降低48优于预测VR 96周在24周和72周在不同的时间分。AUC。
结论基线HBVDNA水平，病毒学非响应在24周和48周在96周ETV单药治疗的的部分viological响应的独立危险因素。在48周的HBVDNA <100IU/ml是一个很好的预测VR在96周的随访过程中。